MAR 0 1 2007 20 1103326.

PRACE THAT ENGTHE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

: Abra, amsson et al.

Serial No.

: 09/581 967

Filed

: June 19 2000

For

: NEW PHARMACEUTICAL

FORMULATIONS

Examiner

: To be assigned

Group Art Unit

: To be assigned

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231

Andrew Fessak

48 528

Agent Name

PTO Reg. No.

Signature

Date of Signature

Assistant Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION

Sir:

Applicants submit this communication and the attached Form PTO-1449 in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. A copy of each of the documents listed on the Form PTO-1449 is enclosed as part of this communication.

TIME OF TRANSMITTAL OF INFORMAT, ON DISCLOSURE STATEMENT

This Information Disclosure Statement is being fi ed before the mailing date of the first Office Action on the merits according to 37 C.F.R. §1.97(b)(3). Therefore, no fee is due in connection with this filing. However, should any fee be deemed necessary in connection with this filing, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 23-1703.

Dated: 0d 23, 2001

Respectfully submitted,

Andrew Fessak Reg. No. 48,528

Agent for Applicants

Customer No. 007470

Agent's Direct Dial: (212) 819-8437

andrew Fessak